What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?

Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 12, 2025

KROS vs. ARGX: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Dec 12, 2025

Buy These 5 Best Value Stocks to Make the Most of P/B Ratio

Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.

Zacks Investment Research • Nov 28, 2025

How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%

The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 26, 2025

KROS or NVZMY: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Nov 26, 2025

Keros Therapeutics Announces Final Results of Tender Offer

LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company's previously announced $375 million capital return program.

GlobeNewsWire • Nov 20, 2025

Keros Therapeutics Announces Preliminary Results of Tender Offer

LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company's previously announced $375 million capital return program.

GlobeNewsWire • Nov 19, 2025

5 Undervalued Stocks That Are Poised for Growth in November

Five undervalued picks - including StoneCo and MillerKnoll - shine with strong growth prospects and low price-to-book ratios this November.

Zacks Investment Research • Nov 13, 2025

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?

The consensus price target hints at a 42.8% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 10, 2025

Keros Therapeutics Reports Third Quarter 2025 Financial Results

LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended September 30, 2025.

GlobeNewsWire • Nov 5, 2025